Krankenhaushygiene up2date 2012; 07(04): 291-304
DOI: 10.1055/s-0032-1325773
Antibiotikaanwendung
© Georg Thieme Verlag KG Stuttgart · New York

Vancomycin-resistente Enterokokken – Epidemiologie, Diagnostik, Typisierung, Trends

Guido Werner
Further Information

Publication History

Publication Date:
11 December 2012 (online)

Kernaussagen
  • Enterokokken/VRE sind klassische opportunistische Infektionserreger mit ausdrücklich hohem Ausbreitungspotenzial im nosokomialen Umfeld.

  • vanA- und vanB-Typ-VRE sind nahezu ausschließlich E. faecium.

  • Einer VRE-Infektion geht meist eine intestinale Besiedlung in Kombination mit weiteren Risikofaktoren (z. B. Antibiotikabehandlung) voraus.

  • Die Inzidenz ist von disponierenden Faktoren des Patienten und dem Aufenthalt in Risikobereichen abhängig.

  • Hospital-assoziierte E. faecium/VRE sind verantwortlich für Häufungen und Ausbrüche in Gesundheitseinrichtungen; diese Stämme unterscheiden sich von kommensalen E. faecium Stämmen (vancomycin-sensibel).

  • Die Ursachen des Auftretens und Häufungen von VRE sind multifaktoriell und können medizinische, hygienische wie auch mikrobiologische Gründe haben.

  • Derzeit vorliegende Infektionspräventions- und Kontrollmaßnahmen orientieren sich weitgehend an MRSA; ein geeigneter Maßnahmenkatalog für VRE sowie dessen Einsatzbereich (z. B. besiedelte/infizierte Patienten, nur Intensivpatienten) wird derzeit kontrovers diskutiert.

 
  • Literatur

  • 1 Kohler W. The present state of species within the genera Streptococcus and Enterococcus. Int J Med Microbiol 2007; 297: 133-150
  • 2 Giraffa G. Enterococci from foods. FEMS Microbiol Rev 2002; 26: 163-171
  • 3 Lester CH, Sandvang D, Olsen SS et al. Emergence of ampicillin-resistant Enterococcus faecium in Danish hospitals. J Antimicrob Chemother 2008; 62: 1203-1206
  • 4 Top J, Willems R, van der Velden S et al. Emergence of clonal complex 17 Enterococcus faecium in The Netherlands. J Clin Microbiol 2008; 46: 214-219
  • 5 Bonten MJ, Willems R, Weinstein RA. Vancomycin-resistant enterococci: why are they here, and where do they come from?. Lancet Inf Dis 2001; 1: 314-325
  • 6 Cetinkaya Y, Falk P, Mayhall CG. Vancomycin-resistant enterococci. Clin Microbiol Rev 2000; 13: 686-707
  • 7 Arias CA, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008; 6: 637-655
  • 8 Werner G, Coque TM, Hammerum AM et al. Emergence and spread of vancomycin resistance among enterococci in Europe. EuroSurveill 2008; 13 pii 19046
  • 9 EARSS. EARSS Annual report 2008. EARSS Annual report 2009; 10: 1-180
  • 10 Klare I, Werner G, Witte W. Enterococci with vancomycin resistance from German hospitals in 2008/2009 (German). Epidemiol Bull 2010; 44: 427-437
  • 11 Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42: 25-S34
  • 12 Baptista M, Rodrigues P, Depardieu F et al. Single-cell analysis of glycopeptide resistance gene expression in teicoplanin-resistant mutants of a VanB-type Enterococcus faecalis. Mol Microbiol 1999; 32: 17-28
  • 13 Abele-Horn M, Hommers L, Trabold R et al. Validation of VITEK 2 version 4.01 software for detection, identification, and classification of glycopeptide-resistant enterococci. J Clin Microbiol 2006; 44: 71-76
  • 14 Song JH, Ko KS, Suh JY et al. Clinical implications of vancomycin-resistant Enterococcus faecium (VRE) with VanD phenotype and vanA genotype. J Antimicrob Chemother 2008; 61: 838-844
  • 15 Werner G, Klare I, Fleige C et al. Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU. Antimicrob Resist Inf Control 2012; 1: 21
  • 16 Werner G, Serr A, Schütt S et al. Comparison of direct cultivation on a selective solid medium, polymerase chain reaction from an enrichment broth, and the BD GeneOhm VanR assay for identification of vancomycin-resistant enterococci in screening specimens. Diagn Microbiol Inf Dis 2011; 70: 512-521
  • 17 Graham M, Ballard SA, Grabsch EA et al. High rates of fecal carriage of nonenterococcal vanB in both children and adults. Antimicrob Agents Chemother 2008; 52: 1195-1197
  • 18 Arias CA, Murray BE. The rise of the Enterococcus: beyond vancomycin resistance. Nature Reviews Microbiol 2012; 10: 266-278
  • 19 Ubeda C, Taur Y, Jenq RR et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Investig 2010; 120: 4332-4341
  • 20 Mascini EM, Bonten MJ. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect 2005; 11: 43-56
  • 21 Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-386
  • 22 Baum H, Dettenkofer M von, Fahr A-M et al. [Harmonised recommendations Baden-Württemberg – management of patients with glycopeptide-resistant enterococci]. Hyg Med 2006; 31: 30-32
  • 23 Vonberg RP, Chaberny IF, Kola A et al. [Prevention and control of the spread of vancomycin-resistant enterococci: results of a workshop held by the German Society for Hygiene and Microbiology]. Anaesthesist 2007; 56: 151-157
  • 24 Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 1995; 16: 105-113
  • 25 Mascini EM, Bonten MJ. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin Microbiol Infect 2005; 11: 43-56
  • 26 Witte W, Heuck D, Klare I et al. Stellungnahme zu “Recommendations for preventing the spread of vancomycin resistance”. Mikrobiologe 1996; 6: 134-136
  • 27 Siegel JD, Rhinehart E, Jackson M et al. Management of multidrug-resistant organisms in healthcare settings, 2006. In: CDC Centers for Disease Control and Prevention. 74. ed. Atlanta: CDC; 2006: 1-74
  • 28 Bourdon N, Lemire A, Fines-Guyon M et al. Comparison of four methods, including semi-automated rep-PCR, for the typing of vancomycin-resistant Enterococcus faecium. J Microbiol Methods 2011; 84: 74-80
  • 29 Werner G, Klare I, Konstabel C et al. The current MLVA typing scheme for Enterococcus faecium does not discriminate enough to resolve epidemic-virulent, hospital-adapted clonal types. BMC Microbiol 2007; 7: 28
  • 30 van Schaik W, Willems RJ. Genome-based insights into the evolution of enterococci. Clin Microbiol Infect 2010; 16: 527-532
  • 31 Willems RJ, Hanage WP, Bessen DE et al. Population biology of gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35: 872-900
  • 32 Klare I, Konstabel C, Mueller-Bertling S et al. Spread of ampicillin/vancomycin-resistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur J Clin Microbiol Inf Dis 2005; 24: 815-825
  • 33 Werner G, Fleige C, Geringer U et al. IS element IS16 as a molecular screening tool to identify hospital-associated strains of Enterococcus faecium. BMC Infect Dis 2011; 11: 80
  • 34 Klare I, Werner G, Witte W et al. 4.1.3. Enterococcus spp. In: Kresken M, Wallmann J, Kern W, eds. GERMAP 2008. Rheinbach: Antiinfectives Intelligence Gesellschaft; 2009
  • 35 Werner G, Coque TM, Hammerum AM et al. Emergence and spread of vancomycin resistance among enterococci in Europe. EuroSurveill 2008; 13 pii 19046
  • 36 Klare I, Fleige C, Geringer U et al. Performance of three chromogenic VRE screening agars, two Etest® Vancomycin protocols and different microdilution methods in detecting vanB genotype Enterococcus faecium with varying levels of vancomycin expression. Diagn Microbiol Inf Dis 2012; 74: 171-176